Purpose Myositis as a rare manifestation of COVID-19 is only recently being reported. This
review examines the current literature on COVID-19-induced myositis focusing on�…

The manifestations of COVID-19 have been evolving over time. Various post-COVID-19
syndromes are being recognised. Various viruses have been implicated in the pathogenesis�…

The first EULAR provisional recommendations on the management of rheumatic and
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome�…

At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development�…

ABSTRACT Introduction Coronavirus disease 2019 (COVID-19) is an infectious disease
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection�…

Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the
treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can�…

Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory
therapies in COVID-19. Methods According to the EULAR standardised operating�…

Severe acute respiratory coronavirus-2 syndrome (SARS-CoV-2) is a well-known pandemic
infectious disease caused by an RNA virus belonging to the coronaviridae family. The most�…

A new coronavirus disease (COVID-19) has already affected millions of people in 213
countries. The possibilities of treatment have been reviewed in recent publications but there�…

With the emerging success of the COVID-19 vaccination programs, the incidence of acute
COVID-19 will decrease. However, given the high number of people who contracted SARS�…